Interviewee: Brian Druker. Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process. (DNAi Location: Applications > Genes and medicine > Drug design > Brian Druker > Approval in record time)

And fortunately those phase 1 clinical trials were remarkably successful and then there was no looking back. Now Novartis at that point recognizing that they had a remarkably successful drug put resources behind this development like you couldn't imagine and accelerated the development of this drug through phase 2 and phase 3 and to market approval in record time. And so all the time that was lost while they were trying to make decisions about developing was caught up on the other end and they really deserve a huge amount of credit for once they realized they had something so successful for putting the major resources into its development that got it to patients as quickly as it did.

chronic myeloid leukemia,phase 1 clinical trials,brian druker,gleevec,time brian,location applications,market approval,major resources,dnai,record time,interviewee,cml,phase 3,novartis,phase 2,leukemia,genes,decisions,medicine